Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AVTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| AVTX-002 | Non-Eosinophilic Asthma | Phase 2 · NCT05288504 | Completed |
| AVTX-009 Regimen 1 | Hidradenitis Suppurativa | Phase 2 · NCT06603077 | Completed |
| AVTX-009 Regimen 2 | Hidradenitis Suppurativa | Phase 2 · NCT06603077 | Completed |
| CERC-301 | Major Depressive Disorder | Phase 2 · NCT01941043 | Completed |
| FP01 | Chronic Refractory Cough | Phase 2 · NCT01703923 | Completed |
| Camoteskimab (AEVI-007) | Multiple Myeloma | Phase 1 · NCT04671251 | Completed |
| mTOR Kinase Inhibitor CERC-006 | Lymphatic Malformation | Phase 1 · NCT04994002 | Withdrawn |
| MDGN-002 | Crohn Disease | Phase 1 · NCT03169894 | Terminated |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AVTX holds $393M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.8M/quarter from operations, an estimated runway of 74.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 30 · Moderate
Based on our current operating plans, we expect that our existing cash, cash equivalents and investments are sufficient to fund operations into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AVTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Commodore Capital LP | Institution (13G, 5%+) | 5,721,109 | 9.89% | 2026-06-11 |
| Farallon Capital Management, L.L.C. | Institution (13G, 5%+) | 3,974,000 | 6.87% | 2026-09-30 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 3,610,000 | 6.24% | 2026-06-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 3,483,099 | 6.02% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,415,731 | 5.91% | 2026-06-30 |
| Caligan Partners LP | Institution (13G, 5%+) | 3,163,866 | 5.47% | 2026-06-30 |
| TCG Crossover GP II, LLC | 5%+ holder (13G) | 3,017,120 | 5.22% | 2026-05-05 |
| Affinity Asset Advisors, LLC | Institution (13G, 5%+) | 2,900,000 | 5.02% | 2026-06-30 |
| Trails Edge Capital Partners, LP | Institution (13G, 5%+) | 2,803,761 | 4.85% | 2026-10-22 |
| Garry Arthur Neil Chief Executive Officer, Director |
Insider | 190,314 | 0.33% | 2026-05-21 |
| Mittie Doyle Chief Medical Officer · +237,484 options |
Insider | 51,776 | 0.09% | 2026-08-28 |
| Christopher Ryan Sullivan Chief Financial Officer · +189,663 options |
Insider | 39,900 | 0.07% | 2026-09-16 |
Share count 57,823,083 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →